id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-D-1211-0147,FDA,FDA-2015-D-1211,Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance Level 2 Update Final AUGUST 2020,Other,Guidance,2020-08-31T04:00:00Z,2020,8,2020-08-31T04:00:00Z,,2024-11-12T23:24:17Z,,1,0,0900006484828fc5
FDA-2015-D-1211-0136,FDA,FDA-2015-D-1211,Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products,Other,Guidance,2020-06-17T04:00:00Z,2020,6,2020-06-17T04:00:00Z,,2023-02-28T14:36:33Z,,0,0,09000064846f63b7
FDA-2015-D-1211-0135,FDA,FDA-2015-D-1211,"Revised Recommendations for Reducing the Risk of Human
Immunodeficiency Virus Transmission by Blood and Blood Products;
Guidance for Industry; Availability",Notice,Notice of Data Availability,2020-06-17T04:00:00Z,2020,6,2020-06-17T04:00:00Z,,2023-02-28T14:29:54Z,2020-13051,0,0,09000064846f5d6b
FDA-2015-D-1211-0111,FDA,FDA-2015-D-1211,Ref 37 - Custer - Transfusion-transmissible infection,Supporting & Related Material,Background Material,2020-04-03T04:00:00Z,2020,4,,,2020-04-03T14:28:54Z,,0,0,0900006484485938
FDA-2015-D-1211-0109,FDA,FDA-2015-D-1211,Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Other,Guidance,2020-04-03T04:00:00Z,2020,4,2020-04-03T04:00:00Z,,2023-02-28T14:41:01Z,,0,0,0900006484485934
FDA-2015-D-1211-0110,FDA,FDA-2015-D-1211,Reference 26 - Custer - Blood DROPS,Supporting & Related Material,Background Material,2020-04-03T04:00:00Z,2020,4,,,2020-04-03T14:28:04Z,,0,0,0900006484485937